Hangwen Li is the founder of Stemirna. Stemirna has raised $188M in total funding. Latest round: Series C. Based in Shanghai, China.
Hangwen Li is the CEO of Stemirna Therapeutics, a Chinese company specializing in mRNA technology. Stemirna Therapeutics has raised RMB 1.2 billion ($188 million) to develop an mRNA vaccine against COVID-19, with plans to build facilities to produce 100 million doses annually. The company's COVID-19 vaccine candidate, SW-0123, is in Phase 1 study in China and is preparing for Phase 2 and 3 clinical trials overseas. Prior to this, Stemirna secured approximately $14 million in Series A funding.
Full founder directory · Investor directory · Company funding database · Fundraising library